Calamos Wealth Management LLC Sells 4,322 Shares of Astrazeneca Plc $AZN

Calamos Wealth Management LLC cut its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 13.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,227 shares of the company’s stock after selling 4,322 shares during the quarter. Calamos Wealth Management LLC’s holdings in Astrazeneca were worth $5,370,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. IHT Wealth Management LLC boosted its holdings in shares of Astrazeneca by 0.3% in the 4th quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock worth $3,076,000 after buying an additional 54 shares during the last quarter. Visionary Wealth Advisors increased its holdings in Astrazeneca by 1.5% during the fourth quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after buying an additional 60 shares during the last quarter. Vista Investment Management increased its holdings in Astrazeneca by 0.3% during the fourth quarter. Vista Investment Management now owns 21,215 shares of the company’s stock worth $3,723,000 after buying an additional 60 shares during the last quarter. Kestra Investment Management LLC raised its position in Astrazeneca by 1.9% in the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after acquiring an additional 63 shares during the period. Finally, Luken Investment Analytics LLC boosted its stake in Astrazeneca by 4.3% in the fourth quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after acquiring an additional 64 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Bank of America reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Finally, UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca struck an exclusive global license deal for the lung-cancer drug Zegfrovy, a move that could strengthen its oncology pipeline and long-term growth prospects. Article Title
• Positive Sentiment: UBS reiterated a Buy rating ahead of second-quarter results, saying AstraZeneca should deliver solid earnings and revenue. Article Title
• Neutral Sentiment: Analysts from both the U.S. and U.K. cited a mixed setup, with some optimism on near-term results but limited scope for AstraZeneca to raise full-year guidance. Article Title
• Negative Sentiment: HSBC downgraded AstraZeneca to Hold and cut its price target after the Wainua Phase 3 failure, saying the setback weakens the stock’s bull case. Article Title

Astrazeneca Trading Down 1.1%

Shares of AZN opened at $169.79 on Tuesday. The business’s 50-day moving average price is $183.38 and its 200-day moving average price is $188.67. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The stock has a market cap of $263.32 billion, a PE ratio of 25.49, a P/E/G ratio of 1.39 and a beta of 0.24. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. On average, equities analysts forecast that Astrazeneca Plc will post 10.28 EPS for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.